Differential Effects of Depleting versus Programming Tumor-Associated Macrophages on Engineered T Cells in Pancreatic Ductal Adenocarcinoma.
Animals
Antigens, Neoplasm
Biomarkers, Tumor
Carcinoma, Pancreatic Ductal
/ genetics
Disease Models, Animal
Extracellular Matrix
Gene Expression Profiling
Genetic Engineering
Humans
Immunotherapy
Lymphocyte Depletion
Macrophages
/ immunology
Mesothelin
Mice
Mice, Transgenic
Pancreatic Neoplasms
/ genetics
T-Lymphocytes
/ immunology
Pancreatic Neoplasms
Journal
Cancer immunology research
ISSN: 2326-6074
Titre abrégé: Cancer Immunol Res
Pays: United States
ID NLM: 101614637
Informations de publication
Date de publication:
06 2019
06 2019
Historique:
received:
05
07
2018
revised:
05
12
2018
accepted:
09
04
2019
pubmed:
28
4
2019
medline:
6
8
2020
entrez:
28
4
2019
Statut:
ppublish
Résumé
Pancreatic ductal adenocarcinoma (PDA) is a lethal malignancy resistant to therapies, including immune-checkpoint blockade. We investigated two distinct strategies to modulate tumor-associated macrophages (TAM) to enhance cellular therapy targeting mesothelin in an autochthonous PDA mouse model. Administration of an antibody to colony-stimulating factor (anti-Csf1R) depleted Ly6C
Identifiants
pubmed: 31028033
pii: 2326-6066.CIR-18-0448
doi: 10.1158/2326-6066.CIR-18-0448
pmc: PMC6548612
mid: NIHMS1527226
doi:
Substances chimiques
Antigens, Neoplasm
0
Biomarkers, Tumor
0
Msln protein, mouse
0
Mesothelin
J27WDC343N
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
977-989Subventions
Organisme : NCI NIH HHS
ID : R01 CA161112
Pays : United States
Organisme : NCI NIH HHS
ID : R37 CA033084
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA033084
Pays : United States
Organisme : NIAID NIH HHS
ID : T35 AI118620
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA018029
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA015704
Pays : United States
Informations de copyright
©2019 American Association for Cancer Research.
Références
Immunity. 1999 Sep;11(3):299-308
pubmed: 10514008
Clin Cancer Res. 2001 Dec;7(12):3862-8
pubmed: 11751476
Glia. 2005 Sep;51(4):297-305
pubmed: 15846794
Cancer Cell. 2005 May;7(5):469-83
pubmed: 15894267
J Exp Med. 2006 Mar 20;203(3):583-97
pubmed: 16492803
Annu Rev Immunol. 2009;27:669-92
pubmed: 19132917
J Clin Invest. 2010 Jul;120(7):2627-34
pubmed: 20577051
J Immunother. 2010 Oct;33(8):828-33
pubmed: 20842054
Science. 2011 Mar 25;331(6024):1612-6
pubmed: 21436454
J Exp Med. 2011 May 9;208(5):1069-82
pubmed: 21536742
Nat Rev Immunol. 2012 Mar 22;12(4):253-68
pubmed: 22437938
N Engl J Med. 2012 Jun 28;366(26):2455-65
pubmed: 22658128
Clin Cancer Res. 2012 Aug 15;18(16):4266-76
pubmed: 22896693
Immunity. 2013 Apr 18;38(4):792-804
pubmed: 23601688
Nature. 2013 Jul 11;499(7457):214-218
pubmed: 23770567
Nat Genet. 2013 Oct;45(10):1113-20
pubmed: 24071849
Immunol Rev. 2014 Jan;257(1):145-64
pubmed: 24329795
Oncoimmunology. 2013 Dec 1;2(12):e26968
pubmed: 24498562
Gut. 2014 Nov;63(11):1769-81
pubmed: 24555999
Annu Rev Immunol. 2014;32:659-702
pubmed: 24655300
Cancer Res. 2014 Jun 1;74(11):2913-21
pubmed: 24840647
Carcinogenesis. 2014 Jul;35(7):1451-60
pubmed: 24908682
Clin Cancer Res. 2014 Oct 15;20(20):5157-70
pubmed: 25047706
Cancer Res. 2014 Sep 15;74(18):5057-69
pubmed: 25082815
Cancer Immunol Res. 2015 Apr;3(4):399-411
pubmed: 25678581
Nature. 1989 Nov 30;342(6249):559-61
pubmed: 2573841
Immunity. 2015 Jun 16;42(6):1143-58
pubmed: 26070485
Lancet Oncol. 2015 Aug;16(8):949-56
pubmed: 26179200
Cancer Cell. 2015 Nov 9;28(5):638-652
pubmed: 26525103
J Immunother Cancer. 2015 Dec 15;3:42
pubmed: 26674611
Cancer Discov. 2016 Apr;6(4):400-413
pubmed: 26896096
NPJ Breast Cancer. 2016;2:null
pubmed: 26998515
J Immunol. 2016 Jul 1;197(1):179-87
pubmed: 27217585
Cell Rep. 2016 Jun 21;15(12):2719-32
pubmed: 27292635
Cancer Cell. 2016 Oct 10;30(4):651
pubmed: 27728809
Nat Rev Clin Oncol. 2017 Jul;14(7):399-416
pubmed: 28117416
J Clin Invest. 2017 Apr 3;127(4):1254-1270
pubmed: 28287406
Oncotarget. 2017 Mar 28;8(13):21526-21538
pubmed: 28423526
Nature. 2017 May 25;545(7655):495-499
pubmed: 28514441
Cancer Cell. 2017 Aug 14;32(2):185-203.e13
pubmed: 28810144
Cancer Treat Rev. 2017 Nov;60:32-43
pubmed: 28869888
Immunity. 2017 Sep 19;47(3):597
pubmed: 28930665
Elife. 2017 Oct 05;6:
pubmed: 28980940
Immunity. 2017 Oct 17;47(4):621-634
pubmed: 29045897
Cancer Immunol Res. 2017 Nov;5(11):978-991
pubmed: 29066497
Cancer Immunol Res. 2017 Dec;5(12):1109-1121
pubmed: 29097420
Proc Natl Acad Sci U S A. 2017 Nov 28;114(48):E10418-E10427
pubmed: 29133420
Cancer Cell. 2017 Nov 13;32(5):654-668.e5
pubmed: 29136508
J Exp Med. 2018 Mar 5;215(3):877-893
pubmed: 29436395
J Exp Med. 2018 Mar 5;215(3):859-876
pubmed: 29436396
Cell Rep. 2018 May 1;23(5):1448-1460
pubmed: 29719257
Proc Natl Acad Sci U S A. 1996 Jan 9;93(1):136-40
pubmed: 8552591